Objective: In the literature, children and families have been reported to show high rates of non-adherence to psychopharmacological treatment. This study aimed to investigate psychotropic drug selection, repeat prescription rates, and drug compliance in children who presented to the psychiatry department of a university hospital.
Method: Patients examined at the Ondokuz Mayis University Child Psychiatry Outpatient Clinic were included in the study. Patients were retrospectively screened with the Nucleus® system.
Results: 12607 patients were included the study, 8889 of whom (70.4%) had received at least one prescription during the follow-up. The mean age of the patients was 12.1±5.0 years and the male sex ratio was 57.4%. The highest-prescribed drug groups were antipsychotics (32.7%) and stimulants (32.5%). A total of 38432 psychotropic drug prescriptions were made. Patients using psychotropic drugs were given prescriptions 4.32 times on average during this time period, while 2356 patients (26.2%) received one prescription.
Conclusions: Over the time period of the study, one out of every four patients who used psychotropic medication only received one prescription. Many of the psychotropic drugs used in children and adolescents are part of long-term treatments, and we observed a high rate of non-adherence to psychopharmacological treatment in children and families. For future research, we recommend to include factors affecting treatment adherence in children and families.
Amaç: Literatürde, çocuk ve ailelerin yüksek oranlarda psikofarmakolojik tedaviye uyumsuzluk gösterdiği bildirilmiştir. Bu çalışmada bir üniversite hastanesi psikiyatri bölümüne başvuran çocuklarda psikotrop kullanım sıklığının saptanması, tekrar reçetelenme oranları ile tedavi uyumunun araştırılması amaçlanmıştır.
Yöntem: Ondokuz Mayıs Üniversitesi Çocuk Psikiyatri Polikliniği’nde muayene edilen hastalar çalışmaya dahil edilmiştir. Hastalar retrospektif olarak Nucleus® poliklinik sistemi ile taranmıştır.
Bulgular: Üç yıllık zaman periyodunda 12607 kayıtlı hastaya ulaşılmıştır. Hastaların yaş ortalaması 12.1±5.0 ve erkek cinsiyet oranı %57.4’tü. En yüksek oranda reçetelenen ilaç grubu %32.7 ile antipsikotikler ve %32.5 ile stimulan ilaçlar olduğu tespit edilmiştir. Poliklinik kontrolleri sırasında 8.889 hasta (%70.4) en az bir kez reçetelendirilmiştir ve toplam 38432 adet psikotrop ilaç reçete edilmiştir. Psikotrop kullanan hastalar çalışma zaman periyodunda ortalama 4.32 kez reçetelendirilmiştir ve 2356 hasta (%26.2) bir kere reçetelendirilmiştir.
Tartışma: Çalışmanın zaman aralığında, psikotrop ilaç kullanan her dört hastadan biri sadece bir kez reçetelendirilmiştir. Psikotrop ilaçların bir çoğu uzun süreli tedavilerin parçasıdır ve çalışmamızdaki veriler ile hastaların yüksek oranda tedaviye devam etmediği gözlenmiştir. Çocuk, ergenler ve ailelerinde ilaç uyumunu etkileyen faktörlere ait çalışmalara ihtiyaç duyulmaktadır.
REFERENCES
1.Kieling C, Baker-Henningham H, Belfer M, Conti G, Ertem I, Omigbodun O, Rohde LA, Srinath S, Ulkuer N, Rahman A. Child and adolescent mental health worldwide: evidence for action. Lancet 2011; 378:1515-1525.
2.Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283:1025-1030.
3.Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002; 41:514-521.
4.Aydin N, Cetin M, Kurt E, Savas H, Acikel C, Kilic S, Basoglu C, Turkcapar H. A report by Turkish Association for Psychopharmacology on the psychotropic drug usage in Turkey and medical, ethical and economical consequences of current applications. Bulletin of Clinical Psychopharmacology 2013; 23:390-402.
5.Baykara A, Miral S, Boztok A. Drug use in child psychiatry. Medical Journal of Izmir State Hospital 1992; 3:449-454. (Turkish).
6.Aras S, Tas FV, Unlu G. Alterations in medication in a child and adolescent psychiatric outpatient clinic. Bulletin of Clinical Psychopharmacology 2005; 15:127-133. (Turkish)
7.Karaman D, Koray K, Durukan I. Drug use in patients presenting to a child and adolescent policlinic. Anatolian Journal of Clinical Investigation 2012; 6:225-230. (Turkish)
8.Hsia Y, Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992–2001: a population-based study in the UK. Eur J Epidemiol 2009; 24:211-216.
9.Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 2004; 158:753-759.
10.Abbas S, Ihle P, Adler JB, Engel S, Günster C, Linder R, Lehmkuhl G, Schubert I. Psychopharmacological prescriptions in children and adolescents in Germany. Dtsch Arztebl Int 2016; 113:396-403.
11.Koc I, Eryurt MA, Adali T, Seckiner P. Turkey’s demographic change: birth rates, family planning, mother-child health, and changes in deaths under the age of five: 1968–2008. Ankara: Hacettepe University Institut for Population Studies, 2010. (Turkish)
12.Akdemir D, Cetin FC. Clinical Characteristics of Adolescent Admissions to the Child and Adolescent Psychiatry Outpatient Clinic. Turkish Journal of Child and Adolescent Mental Health 2008; 15:5-14. (Turkish)
13.Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009; 15:34-44.
14.Child and adolescent mental health resources: global concerns, implications for the future. Geneva: World Health Organization, 2005.
15.Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 2005; 25:909-917.
16.Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med 1993; 153:1863-1868.
17.Akincigil A, Bowblis JR, Levin C, Walkup JT, Jan S, Crystal S. Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care 2007; 45:363-369.
18.Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63:679-685.
19.Staller JA, Wade MJ, Baker M. Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York. J Child Adolesc Psychopharmacol 2005; 15:57-61.
20.Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 2011; 72:655-670.
21.Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164:942-948.
22.Jensen PS. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073-1086.
23.Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41(Suppl.2):26-49.
24.Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41:776-784.
25.National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 98. 2006.
26.Ambrosini PJ, Bianchi MD, Rabinovich H, Elia J. Antidepressant treatments in children and adolescents. I. Affective disorders. J Am Acad Child Adolesc Psychiatry 1993; 32:1-6.
27.Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J. Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry 1996; 35:1575-1583.
28.DeBar LL, Lynch F, Powell J, Gale J. Use of psychotropic agents in preschool children: associated symptoms, diagnoses, and health care services in a health maintenance organization. Arch Pediatr Adolesc Med 2003; 157:150-157.
29.Mutlu C, Uneri OS, Tanidir C, Gunes H, Copur M, Kilicoglu AG, Adaletli H, Ipek H, Erdogan A. Risperidone use in preschool children with aggressive and destructive behavioral symptoms. Anatolian Journal of Psychiatry 2015; 16:212-219.
30.Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 2009; 28:770-781.
31.Governale L, Mehta H. Outpatient use of atypical antipsychotic agents in the pediatric population: years 2004–2008. US Food and Drug Administration, 2009.
32.Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003; 64:1039-1047.
33.Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47:9-20.
34.Ozbek A, Bozabali OG. The use of psychotropic medication in pre-schoolers. Bulletin of Clinical Psychopharmacology 2003; 13:57-64. (Turkish)
35.Haynes RB, Sackett DL, Taylor DW. Compliance in Health Care. Baltimore, M.D: John Hopkins Press; 1978.
36.LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000; 9:1169-1175.